Literature DB >> 28300466

Selection of the initial design for the two-stage continual reassessment method.

Xiaoyu Jia1, Anastasia Ivanova2, Shing M Lee3.   

Abstract

In the two-stage continual reassessment method (CRM), model-based dose escalation is preceded by a pre-specified escalating sequence starting from the lowest dose level. This is appealing to clinicians because it allows a sufficient number of patients to be assigned to each of the lower dose levels before escalating to higher dose levels. While a theoretical framework to build the two-stage CRM has been proposed, the selection of the initial dose-escalating sequence, generally referred to as the initial design, remains arbitrary, either by specifying cohorts of three patients or by trial and error through extensive simulations. Motivated by a currently ongoing oncology dose-finding study for which clinicians explicitly stated their desire to assign at least one patient to each of the lower dose levels, we proposed a systematic approach for selecting the initial design for the two-stage CRM. The initial design obtained using the proposed algorithm yields better operating characteristics compared to using a cohort of three initial design with a calibrated CRM. The proposed algorithm simplifies the selection of initial design for the two-stage CRM. Moreover, initial designs to be used as reference for planning a two-stage CRM are provided.

Entities:  

Keywords:  Adaptive design; CRM; dose finding; indifference intervals; initial design; phase I study; start-up rule

Mesh:

Year:  2017        PMID: 28300466      PMCID: PMC5383510          DOI: 10.1080/10543406.2017.1290650

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  11 in total

1.  A simple technique to evaluate model sensitivity in the continual reassessment method.

Authors:  Ying Kuen Cheung; Rick Chappell
Journal:  Biometrics       Date:  2002-09       Impact factor: 2.571

2.  Continual reassessment method: a likelihood approach.

Authors:  J O'Quigley; L Z Shen
Journal:  Biometrics       Date:  1996-06       Impact factor: 2.571

3.  The current design of oncology phase I clinical trials: progressing from algorithms to statistical models.

Authors:  Thomas M Braun
Journal:  Chin Clin Oncol       Date:  2014-03

4.  Continual Reassessment and Related Dose-Finding Designs.

Authors:  John O'Quigley; Mark Conaway
Journal:  Stat Sci       Date:  2010       Impact factor: 2.901

5.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Authors:  J O'Quigley; M Pepe; L Fisher
Journal:  Biometrics       Date:  1990-03       Impact factor: 2.571

6.  Design and analysis of phase I clinical trials.

Authors:  B E Storer
Journal:  Biometrics       Date:  1989-09       Impact factor: 2.571

7.  Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.

Authors:  S Percy Ivy; Lillian L Siu; Elizabeth Garrett-Mayer; Larry Rubinstein
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

8.  Bivariate isotonic design for dose-finding with ordered groups.

Authors:  Anastasia Ivanova; Kai Wang
Journal:  Stat Med       Date:  2006-06-30       Impact factor: 2.373

9.  Continual reassessment method for ordered groups.

Authors:  John O'Quigley; Xavier Paoletti
Journal:  Biometrics       Date:  2003-06       Impact factor: 2.571

10.  Model calibration in the continual reassessment method.

Authors:  Shing M Lee
Journal:  Clin Trials       Date:  2009-06       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.